

Discovery of a First-in-Class Oral Small-Molecule TL1A Inhibitor for Inflammatory Bowel Disease

ILAb Co. Ltd.



IMMUNOLOGY	Candidate
Product Type	Small molecules
Indication	Inflammatory Bowel Disease (IBD)
Target	TL1A (TNFSF15)
MoA(Mechanism of Action)	• TL1A - DR3 signaling drives chronic intestinal inflammation through activation of Th1, Th2, Th9, and Th17 immune responses. • TP-0087 is an oral small molecule designed to modulate the TL1A-DR3 axis and suppress chronic inflammatory signaling in IBD. • Potential therapeutic benefits include immune regulation, prevention of disease recurrence, mucosal protection, and anti-fibrotic activity.
Competitiveness	• Oral small-molecule approach with potential advantages in patient convenience, dosing flexibility, and long-term compliance versus antibody therapies. • Differentiated strategy focused on long term disease management in IBD. • Potential combination and indication expansion opportunities across the antibody-dominated TL1A therapeutic landscape.
Development Stage	Candidate
Route of Administration	Oral administration

Any unauthorized distribution or reproduction of this material is strictly prohibited.